{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:37:09Z","timestamp":1770536229356,"version":"3.49.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 26-year-old man presented with a retroperitoneal mass with left urinary tract obstruction and hydronephrosis recently. <jats:sup>18<\/jats:sup>F-FDG PET\/CT showed the retroperitoneal mass had intense and homogeneous FDG avidity. In <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT, the retroperitoneal mass showed intense radioactivity without other organ involvements. The patient was finally diagnosed with idiopathic retroperitoneal fibrosis. After treatment, the follow-up CT showed significant decrease in size of the retroperitoneal mass. The current case indicated that idiopathic retroperitoneal fibrosis had active uptake of <jats:sup>68<\/jats:sup>Ga-FAPI.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003402","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T23:43:02Z","timestamp":1605915782000},"page":"175-176","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Idiopathic Retroperitoneal Fibrosis With Intense Uptake of 68Ga-Fibroblast Activation Protein Inhibitor and 18F-FDG"],"prefix":"10.1097","volume":"46","author":[{"given":"Qingqing","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"bib2-20250621","article-title":"68Ga-NOTA-FAPI-04 PET\/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [18F] FDG PET\/CT","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-019-04346-z","article-title":"FAPI-PET\/CT improves staging in a lung cancer patient with cerebral metastasis","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/RLU.0000000000002914","article-title":"Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in 68Ga-FAPI PET\/CT","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/RLU.0000000000002919","article-title":"Recurrent immunoglobulin G4\u2013related disease shown on 18F-FDG and 68Ga-FAPI PET\/CT","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00259-019-04478-2","article-title":"IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET\/CT","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20250621","article-title":"Fibroblast activation protein targeted PET\/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET\/CT [published online June 8, 2020]","year":"2020","journal-title":"J Nucl Med"},{"key":"bib12-20250621","article-title":"[18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of tuberculous lesions","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2967\/jnumed.119.226993","article-title":"Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04","volume":"60","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:05:00Z","timestamp":1750539900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003402","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,18]]}}}